Biotechnology Companies in the News – September 2012

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.

September 14
Proteonomix Announces Agreement with the University of Medicine and Dentistry of New Jersey (UMDNJ) to Conduct a Phase 1 Trial with UMK-121 in End-Stage Liver Disease

September 13
Cyclacel Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

Senesco Announces First Dose of SNS01-T in Cohort 2 of Phase 1b/2a Study in Multiple Myeloma Trial

The Sixth Annual Managed Markets Summit Opens Next Week in Las Vegas

Immunomedics to Present at 2012 UBS Global Life Sciences Conference

Bristol-Myers Squibb to Present at UBS Global Life Sciences Conference

Paragon Names Integrated Marketing Innovation Practice Lead for Advisory Services

NPS Pharmaceuticals to Present at UBS Global Life Sciences Conference

Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax

September 12
Proteonomix Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial with UMK-121 in End-Stage Liver Disease

September 11
Bristol-Myers Squibb Foundation Announces Five New Grants to Advance Cancer Nursing Skills in Central and Eastern Europe

September 10
Combining SNS01-T with Bortezomib Significantly Increases Its Effectiveness in Model of Multiple Myeloma

New Data Demonstrating Potency of Durata Therapeutics’ Dalbavancin Against Bacterial Pathogens Presented at ICAAC 2012

Merck to Present at Morgan Stanley Global Healthcare Conference

Merck Announces New Phase III Data for Suvorexant, an Investigational Insomnia Medicine

CircuLite® Presents Positive Hemodynamic, Exercise Tolerance and Quality of Life Data for SYNERGY® Circulatory Support System at Heart Failure Society of America Scientific Meeting

Merck Prices $2.5 Billion Debt Offering

September 7
Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

September 6
Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn’s Disease

Derma Sciences Launches MEDIHONEY® HCS in the U.S.

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

ADMA Biologics to Present at the Rodman & Renshaw Annual Global Investment Conference

Durata Therapeutics Completes Target Enrollment in Phase 3 DISCOVER 1 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in abSSSI Patients

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference

PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

NPS Pharmaceuticals to Present at Upcoming Conferences

CRI Lifetree to Conduct First-of-Kind Study to Investigate Genetic and Behavioral Markers in Addiction to Prescribed Pain Medications

Columbia Laboratories Regains Compliance with Nasdaq Listing Standards

Amicus Therapeutics Presents Updated Patient Screening Profiles from Phase 3 Fabry Study

Apremilast Palace Program Demonstrates Robust and Consistent Statistically Significant Clinical Benefit Across Three Pivotal Phase III Studies (PALACE-1, 2 & 3) in Psoriatic Arthritis

September 5
CircuLite® Receives CE Marking Approval for SYNERGY® Circulatory Support System

NPS Pharmaceuticals Expects to File Natpara™ BLA in Mid-2013

Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference

Derma Sciences to Present at the Rodman and Renshaw Annual Global Investment Conference

Senesco to Present at Rodman & Renshaw Annual Global Investment Conference

September 4
Revestive® (teduglutide) Receives European Marketing Authorization for the Treatment of Adults with Short Bowel Syndrome (SBS)

Two New Executives Join VaxInnate Management Team

Proteonomix Engages Numoda Corporation for Clinical Trial Services

Top 20 Drug Companies Employ an Average 136 MSLs

Sophion Announces the Qube – the Next Generation Platform for Ion Channel Screening

Soligenix Announces $300,000 NCI SBIR Grant Award Supporting a Phase 2 Trial of orBec® as a Treatment for Chronic GI GVHD

Allergan Opens New Research and Development Center in Bridgewater, New Jersey

Aegerion Pharmaceuticals Announces Participation at Morgan Stanley and Think Equity Healthcare Conferences

August 31
Lexicon Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference

Spiriva® HandiHaler® (tiotropium bromide inhalation powder) and COPD Data to be Presented at the 2012 European Respiratory Society (ERS) Congress

August 30
NPS Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference

Antares Pharma to Present at the Stifel Nicolaus 2012 Healthcare Conference

Soligenix Announces Positive Phase 1B Clinical Results with RiVax™, Its Vaccine Against Ricin Toxin Exposure

Ironwood and Forest Announce FDA Approval of Linzess(Tm) (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

The Medicines Company to Participate in Two Investor Conferences 19th Annual Newsmakers in the Biotech Industry Conference and Morgan Stanley Global Healthcare Conference

August 29
Durata Therapeutics Announces Five Abstracts Concerning Dalbavancin and Management of abSSTI at ICAAC 2012

Protalex, Inc. Completes Analysis of Data from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis

Cyclacel to Present at Stifel Nicolaus 2012 Healthcare Conference

August 28
Durata Therapeutics to Present at BioCentury NewsMakers Conference

AstraZeneca Entices Roche Exec to Take on CEO Challenge

Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin

August 27
Celgene Corporation to Present at Investor Conferences in September

Senesco Technologies Receives Notice of Non-Compliance from NYSE MKT

Amicus Therapeutics Announces Posters and Presentations at Society for the Study of Inborn Errors of Metabolism Symposium 2012

August 26
New Novartis Phase II data show LCZ696 may provide clinical benefits in patients with a difficult-to-treat form of heart failure

August 24
Cyclacel Announces Reverse Stock Split

Presentation of Second Quarter and First Half 2012 Results

Dendreon Announces Webcast Presentations at Upcoming Conferences

Forest Announces Certified Annual Meeting Results

August 23
Columbia Laboratories Will Present on September 6 at Stifel Nicolaus Healthcare Conference

Advaxis Announces Two Abstracts Accepted for Presentation at SITC Annual Meeting

Immunomedics Announces Fiscal 2012 Results

Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C

August 22
Photocure ASA – Presents Second Quarter and First Half Year 2012 Report on Friday August 24

Proteonomix Licenses Exclusive Worldwide Rights to Novel Anti-Tumor Technology

Edge Therapeutics Appoints Drug-Delivery Luminary Dr. Robert Langer to Chair Scientific Advisory Committee

Two Medimmune Facilities Awarded Prestigious Leed® Gold Building Certification

August 21
NPS Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Gattex® (teduglutide)

Cancer Genetics, Inc. Named to the 2012 Inc. 500|5000 List

August 20
ELIQUIS® (apixaban) Data Analyses to Be Presented at European Society of Cardiology Congress 2012

GE Healthcare Recognized by Industrial Designers Society of America for Design Excellence

August 17
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Cellular Voice and Data Services

August 16
Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies

August 15
Bristol-Myers Squibb Announces Specialty Pharmacy Patient Management Programs for Sprycel® (dasatinib) Patients

A Focus on Specialty Pharmacy at Las Vegas Pharmaceutical Conference

Unigene and Nordic Bioscience Announce Preliminary Selection of Lead Compound for Treating Type 2 Diabetes

August 14
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Disposable Anesthesia Products

Cyclacel Reports Second Quarter 2012 Financial Results

ADMA Biologics Reports 2012 Second Quarter Results

IMS Health Expands Suite of Syndicated, Web-based Analytics with Acquisition of PharmaDeals Ltd.

Proteonomix Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial with UMK-121 in Patients with End-Stage Liver Disease

Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference

Nephros Reports Second Quarter 2012 Financial Results

Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review of Lomitapide NDA

August 13
NPS Pharmaceuticals Announces Extension of Action Date for Gattex® NDA to December 30, 2012

Senesco Announces Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T in Cancer Model

DSP Clinical President and Founder Darlene Panzitta Named to the PharmaVOICE 100 List of the Most Influential People in Life Sciences Industries

New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma

IGI Laboratories Announces 2nd Quarter 2012 Results

Sanofi Announces FDA Approval for Auvi-Q™, First Voice-Guided Epinephrine Auto-Injector for Patients with Life-Threatening Allergies

Pfizer and Astrazeneca Enter Into Agreement for Over-the-Counter Nexium

August 10
Lexicon Pharmaceuticals to Present at the Wedbush PacGrow 2012 Management Access Conference

Celldex Reports Second Quarter 2012 Financial Results

Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments

August 9
Unigene Announces Second Quarter 2012 Financial Results

Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program

Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin

Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.

Medical Science Liaison and Sales Team Collaborations Prevent Friction in Thought Leader Management

Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Operating Room Accessory Products

IMS Health Expands Access to Allergy Alert Smartphone Application for U.S. Consumers

Peter Alterman Named COO, SAFE-BioPharma Association

Amicus Therapeutics to Present at Canaccord Genuity Growth Conference

Novo Nordisk Increased Operating Profit by 31% in the First Half of 2012 (9 August 2012)

August 8
APCER Pharma Launches Redesigned Website

Columbia Laboratories Reports Second Quarter 2012 Financial Results

Antares Pharma Reports Second Quarter 2012 Financial and Operating Results

Celldex Therapeutics to Present at the Wedbush PacGrow 2012 Life Sciences: Management Access Conference

Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results

Aegerion Pharmaceuticals Announces Second Quarter 2012 Financial Results

August 7
NPS Pharmaceuticals to Present at Upcoming Conferences

MannKind Corporation Reports 2012 Second Quarter Financial Results